DOCSLIB.ORG

Protein Phosphatase 1 Inhibitor–1 Mediates the Camp-Dependent Stimulation of the Renal Nacl Cotransporter

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protein Phosphatase 1 Inhibitor–1 Mediates the Camp-Dependent Stimulation of the Renal Nacl Cotransporter BASIC RESEARCH www.jasn.org Protein Phosphatase 1 Inhibitor–1 Mediates the cAMP-Dependent Stimulation of the Renal NaCl Cotransporter David Penton,1,2 Sandra Moser,1 Agnieszka Wengi,1 Jan Czogalla,1,2 Lena Lindtoft Rosenbaek,3,4 Fritz Rigendinger,1 Nourdine Faresse,1,2 Joana R. Martins ,1,2 Robert A. Fenton,3 Dominique Loffing-Cueni,1 and Johannes Loffing1,2 1Institute of Anatomy, University of Zurich, Zurich, Switzerland; 2Swiss National Centre for Competence in Research “Kidney Control of Homeostasis,” Zurich, Switzerland; 3Department of Biomedicine, Aarhus University, Aarhus, Denmark; and 4Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark ABSTRACT Background A number of cAMP-elevating hormones stimulate phosphorylation (and hence activity) of the NaCl cotransporter (NCC) in the distal convoluted tubule (DCT). Evidence suggests that protein phosphatase 1 (PP1) and other protein phosphatases modulate NCC phosphorylation, but little is known about PP1’srole and the mechanism regulating its function in the DCT. Methods We used ex vivo mouse kidney preparations to test whether a DCT-enriched inhibitor of PP1, protein phosphatase 1 inhibitor–1 (I1), mediates cAMP’seffectsonNCC,andconductedyeast two-hybrid and coimmunoprecipitation experiments in NCC-expressing MDCK cells to explore protein interactions. Results Treating isolated DCTs with forskolin and IBMX increased NCC phosphorylation via a protein kinase A (PKA)–dependent pathway. Ex vivo incubation of mouse kidney slices with isoproterenol, nor- epinephrine, and parathyroid hormone similarly increased NCC phosphorylation. The cAMP-induced stim- ulation of NCC phosphorylation strongly correlated with the phosphorylation of I1 at its PKA consensus phosphorylation site (a threonine residue in position 35). We also found an interaction between NCC and the I1-target PP1. Moreover, PP1 dephosphorylated NCC in vitro, and the PP1 inhibitor calyculin A in- creased NCC phosphorylation. Studies in kidney slices and isolated perfused kidneys of control and I1-KO mice demonstrated that I1 participates in the cAMP-induced stimulation of NCC. Conclusions Our data suggest a complete signal transduction pathway by which cAMP increases NCC phosphorylation via a PKA-dependent phosphorylation of I1 and subsequent inhibition of PP1. This path- way might be relevant for the physiologic regulation of renal sodium handling by cAMP-elevating hor- mones, and may contribute to salt-sensitive hypertension in patients with endocrine disorders or sympathetic hyperactivity. J Am Soc Nephrol 30: ccc–ccc, 2019. doi: https://doi.org/10.1681/ASN.2018050540 Received May 22, 2018. Accepted February 6, 2019. The thiazide-sensitive NaCl cotransporter (NCC) in the renal distal convoluted tubule (DCT) is cru- S.M. and A.W. contributed equally to this study. + cial for the fine-tuning of renal sodium (Na ) Published online ahead of print. Publication date available at reabsorption and hence for the control of BP. www.jasn.org. NCC and the DCT are also critically involved in Correspondence: Prof. Johannes Loffing, University of Zurich, the renal control of potassium (K+), magnesium Institute of Anatomy, Winterthurerstrasse 190, CH-8057 Zurich, (Mg2+), calcium (Ca2+), and acid/base homeosta- Switzerland. Email: johannes.loffi[email protected] sis.1 The crucial role of NCC is evidenced by genetic Copyright © 2019 by the American Society of Nephrology J Am Soc Nephrol 30: ccc–ccc, 2019 ISSN : 1046-6673/3005-ccc 1 BASIC RESEARCH www.jasn.org diseases in which loss-of-function mutations of NCC cause Significance Statement Gitelman syndrome featuring hypokalemic alkalosis, hypo- magnesemia, hypocalciuria, and lowered arterial BP.2 Con- Stimuli that elevate cAMP, including b-adrenergic agonists and versely, enhanced NCC activity due to mutations in its regulating parathyroid hormone, increase phosphorylation (and hence activ- kinases, namely the with no lysine (K) (WNK) WNK1 ity) of the thiazide-sensitive NaCl cotransporter (NCC) in the distal convoluted tubule. The protein phosphatase 1 (PP1) modulates and WNK4, causes familial hyperkalemic hypertension with NCC phosphorylation, but its role and the mechanism regulating hypermagnesemia and hypercalciuria.3 Moreover, mutations its function are obscure. The authors used in vitro and ex vivo ap- in ubiquitin-ligase complex proteins such as kelch-like-3 proaches to demonstrate that a PP1 inhibitor, protein phosphatase (KLHL3) and cullin-3 (CUL3), which control WNK4 stability, 1 inhibitor–1 (I1), mediates the effects of cAMP-elevating hormones 4,5 on NCC. They propose a novel signaling pathway in which protein are also causative of familial hyperkalemic hypertension. The – – kinase A dependent phosphorylation of I1 inhibits the PP1- WNK kinases control NCC activity via the STE20/SPS 1 related dependent dephosphorylation of NCC. Given NCC’s critical role in proline- and alanine-rich kinase (SPAK) and the oxidative renal control of ion homeostasis and BP, this pathway may con- stress–response kinase 1 (OSR1). SPAKand OSR1 directly phos- tribute to the physiologic regulation of NCC and the development phorylate NCC at several serine and threonine residues located of arterial hypertension in the context of abnormal hormonal within the N-terminal tail of the cotransporter.6,7 stimulation. The activity of the WNK-SPAK kinase pathway and NCC is regulated by various factors including the renin-angiotensin- Interestingly, both the catalytic activity and the substrate aldosterone system.8 Although the DCTexpresses the cognate specificity of phosphatases are often modulated by the inter- receptors for angiotensin II and aldosterone, recent work sug- actionwith specific regulatory subunits. Werecently found that gests that the effect of these hormones on NCC is indirectly the endogenous inhibitor 1 (I1) of PP1 is highly expressed in + + mediated via changes in plasma K concentration ([K ]).9,10 the DCT with strong effects on NCC phosphorylation and + Plasma [K ] is proposed to modulate WNK4 activity through arterial BP.22 I1 is a small, 171–amino acid cytosolic protein 2 changes in DCTmembrane voltage and intracellular Cl con- encoded by the Ppp1r1a gene.23 It is expressed in many organs centration.11 Other NCC stimulators such as the b-adrenergic including the brain, skeletal muscle, and the heart, where it is agonist isoproterenol as well as the parathyroid hormone thought to contribute to neuronal plasticity,24 muscle glyco- (PTH) are thought to mediate their effects via intracellular gen metabolism,25 and cardiac contractility and excitabil- cAMP.12–14 Recently, the cAMP-dependent protein kinase ity.23,26 Moreover, I1 was implicated in the control of the (protein kinase A [PKA]) was implicated in the regulation of activity of the Na-K-ATPase in the heart,27 whereas PP1 was WNK4, suggesting that cAMP may also act via the WNK/ found to modulate the inhibitory effect of WNK4 on ROMK SPAK kinase pathway.13 However, these studies were mainly in the kidney.28 PKA phosphorylates I1 at a threonine residue performed in heterologous expression systems and it in position 35 (T35), which activates I1 and makes it a strong 29 remained unclear whether this and/or additional pathways and very specific inhibitor of PP1 with an IC50 value of 1 nM. contribute to the cAMP-dependent regulation of NCC in the Dephosphorylation of T35 by phosphatases such as PP2A and native DCT. Some studies suggested that the kinase OSR1 and calcineurin (PP3) terminates the inhibitory action of I1.26 In- the extracellular signal–regulated kinase (ERK)1/2 mitogen- terestingly, I1 is critically involved in b-adrenergic and cAMP- activated protein kinase (MAPK) are also involved in the activation dependent signaling in skeletal and heart muscle,23,26 and of NCC by catecholamines15 and PTH,16 respectively. I1-deficient mice are partially protected from isoprenaline- Despite the progress on the elucidation of the role and reg- induced cardiac remodeling and arrhythmia.30 ulation of the WNK/SPAK/OSR1 kinase pathway, little is Here,wetestedthehypothesisthatI1isalsocriticallyinvolvedin known about the phosphatases that counterbalance the ac- the cAMP/PKA-dependent stimulation of NCC phosphorylation. tion of these kinases. As yet, three protein phosphatases are Using a variety of ex vivo approaches, we propose a novel signal suggested to modulate NCC phosphorylation: protein phos- transduction pathway in which cAMP-dependent phosphoryla- phatase–1 (PP1), PP3 (calcineurin), and PP4. In Xenopus tion and activation of I1 mediates the effect of cAMP-elevating laevis oocytes, heterologous coexpression of NCC with hormones on NCC phosphorylation and hence activity. PP4 lowered NCC phosphorylation.17 Likewise, pharmaco- logic inhibition of PP1 with calyculin A 18 and of PP3 with tacrolimus19,20 increased NCC phosphorylation in various METHODS experimental settings. The stimulatory effect of PP3 inhibi- tion on NCC may have important clinical implications. In Reagents, Cells, and Antibodies fact, a common side effect of calcineurin-inhibitor treat- Unless otherwise stated, reagents were purchased from Sigma ment is renal Na+ retention and arterial hypertension, which Aldrich (Buchs, Switzerland). Calyculin Awas purchased from correlates with an enhanced urinary excretion of phosphor- Cell Signaling Technologies (Danvers, MA). 8-Br-cAMP; PKI ylated NCC.18,21 Nevertheless, the physiologic role of the 14–22 amide, myristoylated; and H-89 were purchased from different phosphatases in the DCTand the underlying mech- Tocris
Load more

Recommended publications
  • Activation and Phosphorylation of the 'Dense-Vesicle' High-Affinity Cyclic AMP Phosphodiesterase by Cyclic AMP-Dependent Protein Kinase
    Biochem. J. (1989) 260, 27-36 (Printed in Great Britain) 27 Activation and phosphorylation of the 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase by cyclic AMP-dependent protein kinase Elaine KILGOUR, Neil G. ANDERSON and Miles D. HOUSLAY Molecular Pharmacology Group, Department of Biochemistry, University of Glasgow, Glasgow G12 8QQ, Scotland, U.K. Incubation of a hepatocyte particulate fraction with ATP and the isolated catalytic unit of cyclic AMP- dependent protein kinase (A-kinase) selectively activated the high-affinity 'dense-vesicle' cyclic AMP phosphodiesterase. Such activation only occurred if the membranes had been pre-treated with Mg2". Mg2" pre-treatment appeared to function by stimulating endogenous phosphatases and did not affect phosphodiesterase activity. Using the antiserum DV4, which specifically immunoprecipitated the 51 and 57 kDa components of the 'dense-vesicle' phosphodiesterase from a detergent-solubilized membrane extract, we isolated a 32P-labelled phosphoprotein from 32P-labelled hepatocytes. MgCl2 treatment of such labelled membranes removed 32P from the immunoprecipitated protein. Incubation of the Mg2+-pre-treated membranes with [32P]ATP and A-kinase led to the time-dependent incorporation of label into the 'dense- vesicle' phosphodiesterase, as detected by specific immunoprecipitation with the antiserum DV4. The time- dependences of phosphodiesterase activation and incorporation of label were similar. It is suggested (i) that phosphorylation of the 'dense-vesicle' phosphodiesterase by A-kinase leads to its activation, and that such a process accounts for the ability of glucagon and other hormones, which increase intracellular cyclic AMP concentrations, to activate this enzyme, and (ii) that an as yet unidentified kinase can phosphorylate this enzyme without causing any significant change in enzyme activity but which prevents activation and phosphorylation of the phosphodiesterase by A-kinase.
    [Show full text]
  • (PDE 1 B 1) Correlates with Brain Regions Having Extensive Dopaminergic Innervation
    The Journal of Neuroscience, March 1994, 14(3): 1251-l 261 Expression of a Calmodulin-dependent Phosphodiesterase lsoform (PDE 1 B 1) Correlates with Brain Regions Having Extensive Dopaminergic Innervation Joseph W. Polli and Randall L. Kincaid Section on Immunology, Laboratory of Molecular and Cellular Neurobiology, National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland 20852 Cyclic nucleotide-dependent protein phosphorylation plays PDE implies an important physiological role for Ca2+-regu- a central role in neuronal signal transduction. Neurotrans- lated attenuation of CAMP-dependent signaling pathways mitter-elicited increases in cAMP/cGMP brought about by following dopaminergic stimulation. activation of adenylyl and guanylyl cyclases are downre- [Key words: CAMP, cyclase, striatum, dopamine, basal gulated by multiple phosphodiesterase (PDE) enzymes. In ganglia, DARPP-321 brain, the calmodulin (CaM)-dependent isozymes are the major degradative activities and represent a unique point of Cyclic nucleotides, acting as “second messengers”or via direct intersection between the cyclic nucleotide- and calcium effects, regulate a diverse array of neuronal functions, from ion (Ca*+)-mediated second messenger systems. Here we de- channel conductance to gene expression. Hydrolysis of 3’,5’- scribe the distribution of the PDEl Bl (63 kDa) CaM-depen- cyclic nucleotidesto 5’-nucleosidemonophosphates is the major dent PDE in mouse brain. An anti-peptide antiserum to this mechanismfor decreasingintracellular cyclic nucleotide levels. isoform immunoprecipitated -3O-40% of cytosolic PDE ac- This reaction is catalyzed by cyclic nucleotide phosphodiester- tivity, whereas antiserum to PDElA2 (61 kDa isoform) re- ase (PDE) enzymes that constitute a large superfamily (Beavo moved 60-70%, demonstrating that these isoforms are the and Reifsynder, 1990).
    [Show full text]
  • A Novel, Highly Potent and Selective Phosphodiesterase-9 Inhibitor for the Ferrata Storti Foundation Treatment of Sickle Cell Disease
    Red Cell Biology & its Disorders ARTICLE A novel, highly potent and selective phosphodiesterase-9 inhibitor for the Ferrata Storti Foundation treatment of sickle cell disease James G. McArthur,1 Niels Svenstrup,2 Chunsheng Chen,3 Aurelie Fricot,4 Caroline Carvalho,4 Julia Nguyen,3 Phong Nguyen,3 Anna Parachikova,2 Fuad Abdulla,3 Gregory M. Vercellotti,3 Olivier Hermine,4 Dave Edwards,5 Jean-Antoine Ribeil,6 John D. Belcher3 and Thiago T. Maciel4 1Imara Inc., 2nd Floor, 700 Technology Square, Cambridge, MA, USA; 2H. Lundbeck A/S, 3 Haematologica 2020 Ottiliavej 9, 2500 Valby, Denmark; Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; Volume 105(3):623-631 4INSERM UMR 1163, CNRS ERL 8254, Imagine Institute, Laboratory of Excellence GR-Ex, Paris Descartes - Sorbonne Paris Cité University, Paris, France; 5Kinexum, 8830 Glen Ferry Drive, Johns Creek, GA, USA and 6Departments of Biotherapy, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes- Sorbonne Paris Cité University, Paris, France ABSTRACT he most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with Tpleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to the vascular endothelium. Hydroxyurea has been proposed to mediate these effects through a mechanism of increasing cellular cGMP levels. An alternative path to increasing cGMP levels in these cells is through the use of phospho- diesterase-9 inhibitors that selectively inhibit cGMP hydrolysis and increase cellular cGMP levels. We have developed a novel, potent and selective phosphodiesterase-9 inhibitor (IMR-687) specifically for the treatment of Correspondence: SCD.
    [Show full text]
  • Regulation of Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase (PDE1): Review
    95-105 5/6/06 13:44 Page 95 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 18: 95-105, 2006 95 Regulation of calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1): Review RAJENDRA K. SHARMA, SHANKAR B. DAS, ASHAKUMARY LAKSHMIKUTTYAMMA, PONNIAH SELVAKUMAR and ANURAAG SHRIVASTAV Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Cancer Research Division, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon SK S7N 4H4, Canada Received January 16, 2006; Accepted March 13, 2006 Abstract. The response of living cells to change in cell 6. Differential inhibition of PDE1 isozymes and its environment depends on the action of second messenger therapeutic applications molecules. The two second messenger molecules cAMP and 7. Role of proteolysis in regulating PDE1A2 Ca2+ regulate a large number of eukaryotic cellular events. 8. Role of PDE1A1 in ischemic-reperfused heart Calmodulin-stimulated cyclic nucleotide phosphodiesterase 9. Conclusion (PDE1) is one of the key enzymes involved in the complex interaction between cAMP and Ca2+ second messenger systems. Some PDE1 isozymes have similar kinetic and 1. Introduction immunological properties but are differentially regulated by Ca2+ and calmodulin. Accumulating evidence suggests that the A variety of cellular activities are regulated through mech- activity of PDE1 is selectively regulated by cross-talk between anisms controlling the level of cyclic nucleotides. These Ca2+ and cAMP signalling pathways. These isozymes are mechanisms include synthesis, degradation, efflux and seque- also further distinguished by various pharmacological agents. stration of cyclic adenosine 3':5'-monophosphate (cAMP) and We have demonstrated a potentially novel regulation of PDE1 cyclic guanosine 3':5'- monophosphate (cGMP) within the by calpain.
    [Show full text]
  • Characterization of Contractile Machinery of Vascular Smooth Muscles in Hypertension
    life Review Characterization of Contractile Machinery of Vascular Smooth Muscles in Hypertension Qunhui Yang * and Masatoshi Hori Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-3-5841-7940; Fax: +81-3-5841-8183 Abstract: Hypertension is a key risk factor for cardiovascular disease and it is a growing public health problem worldwide. The pathophysiological mechanisms of vascular smooth muscle (VSM) contrac- tion contribute to the development of hypertension. Calcium (Ca2+)-dependent and -independent signaling mechanisms regulate the balance of the myosin light chain kinase and myosin light chain phosphatase to induce myosin phosphorylation, which activates VSM contraction to control blood pressure (BP). Here, we discuss the mechanism of the contractile machinery in VSM, especially RhoA/Rho kinase and PKC/CPI-17 of Ca2+ sensitization pathway in hypertension. The two signal- ing pathways affect BP in physiological and pathophysiological conditions and are highlighted in pulmonary, pregnancy, and salt-sensitive hypertension. Keywords: vascular smooth muscle contraction; hypertension; CPI-17 Citation: Yang, Q.; Hori, M. 1. Introduction Characterization of Contractile Three types of muscle tissues are found in vertebrates: skeletal muscle, cardiac muscle, Machinery of Vascular Smooth and smooth muscle [1]. Muscle contraction depends on the ATP-driven sliding of highly Muscles in Hypertension. Life 2021, organized arrays of actin filaments against arrays of myosin II filaments [2]. In smooth 11, 702. https://doi.org/10.3390/ muscle, phosphorylation at Thr18/Ser19 of the myosin regulatory light chain results in life11070702 myosin ATPase enzymatic activity that induces actin and myosin attachment to regulate smooth muscle contraction [3,4].
    [Show full text]
  • Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
    International Journal of Molecular Sciences Review Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19? Mauro Giorgi 1,*, Silvia Cardarelli 2, Federica Ragusa 3, Michele Saliola 1, Stefano Biagioni 1, Giancarlo Poiana 1 , Fabio Naro 2 and Mara Massimi 3,* 1 Department of Biology and Biotechnology “Charles Darwin”, Sapienza University of Rome, 00185 Rome, Italy; [email protected] (M.S.); [email protected] (S.B.); [email protected] (G.P.) 2 Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University, 00185 Rome, Italy; [email protected] (S.C.); [email protected] (F.N.) 3 Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy; [email protected] * Correspondence: [email protected] (M.G.); [email protected] (M.M.) Received: 10 July 2020; Accepted: 24 July 2020; Published: 27 July 2020 Abstract: In March 2020, the World Health Organization declared the severe acute respiratory syndrome corona virus 2 (SARS-CoV2) infection to be a pandemic disease. SARS-CoV2 was first identified in China and, despite the restrictive measures adopted, the epidemic has spread globally, becoming a pandemic in a very short time. Though there is growing knowledge of the SARS-CoV2 infection and its clinical manifestations, an effective cure to limit its acute symptoms and its severe complications has not yet been found. Given the worldwide health and economic emergency issues accompanying this pandemic, there is an absolute urgency to identify effective treatments and reduce the post infection outcomes. In this context, phosphodiesterases (PDEs), evolutionarily conserved cyclic nucleotide (cAMP/cGMP) hydrolyzing enzymes, could emerge as new potential targets.
    [Show full text]
  • GRAS Notice No. GRN 000728, FDA Has No Questions, Phospholipase C
    .. .. Janet Oesterling Novozymes North America, Inc. 77 Perry Chapel Church Road Franklinton, NC 27525 Re: GRAS Notice No. GRN 000728 Dear Ms. Oesterling: The Food and Drug Administration (FDA, we) completed our evaluation of GRN 000728. We received Novozymes North America, Inc.’s (Novozymes’) notice on August 25, 2017, and filed it on September 8, 2017. We received an amendment containing additional safety information on October 11, 2017. The subject of the notice is phosphoinositide phospholipase C enzyme preparation produced by Bacillus licheniformis expressing a modified synthetic gene encoding a variant of the wild-type phosphoinositide phospholipase C from Pseudomonas sp. 62186 (phosphoinositide phospholipase C enzyme preparation) for use as an enzyme in the degumming of vegetable oils at a maximum level of 1.4 mg Total Organic Solids (TOS)/kg oil. The notice informs us of Novozymes’ view that this use of phosphoinositide phospholipase C enzyme preparation is GRAS through scientific procedures. Commercial enzyme preparations that are used in food processing typically contain an enzyme component that catalyzes the chemical reaction as well as substances used as stabilizers, preservatives, or diluents. Enzyme preparations may also contain components derived from the production organism and from the manufacturing process, e.g., constituents of the fermentation media or the residues of processing aids. Novozymes’ notice provides information about the components in the phosphoinositide phospholipase C enzyme preparation. Per the classification system of enzymes established by the International Union of Biochemistry and Molecular Biology, phosphoinositide phospholipase C is identified by the Enzyme Commission Number 3.1.4.11. The accepted name is phosphoinositide phospholipase C.
    [Show full text]
  • The Characterization of Oligonucleotides and Nucleic Acids Using Ribonuclease H and Mass Spectrometry
    Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 1999 The hC aracterization of Oligonucleotides and Nucleic Acids Using Ribonuclease H and Mass Spectrometry. Lenore Marie Polo Louisiana State University and Agricultural & Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses Recommended Citation Polo, Lenore Marie, "The hC aracterization of Oligonucleotides and Nucleic Acids Using Ribonuclease H and Mass Spectrometry." (1999). LSU Historical Dissertations and Theses. 6923. https://digitalcommons.lsu.edu/gradschool_disstheses/6923 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter free, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps.
    [Show full text]
  • The Tyrosyl-DNA Phosphodiesterase Tdp1 Is a Member of the Phospholipase D Superfamily
    The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily Heidrun Interthal*, Jeffrey J. Pouliot†, and James J. Champoux*‡ *Department of Microbiology, Box 357242, School of Medicine, University of Washington, Seattle, WA 98195-7242; and †Laboratory of Molecular Biology, National Institute of Mental Health, Building 36, Room 1B08, Bethesda, MD 20892-4034 Communicated by Howard A. Nash, National Institutes of Health, Bethesda, MD, August 15, 2001 (received for review May 14, 2001) The phospholipase D (PLD) superfamily is a diverse group of Yersinia pestis murine toxin substantiates this view and reveals proteins that includes enzymes involved in phospholipid metabo- that the active site nucleophile in the reaction is one of the highly lism, a bacterial toxin, poxvirus envelope proteins, and bacterial conserved histidines of the HKD motif (9, 10). In support of the nucleases. Based on sequence comparisons, we show here that the importance of the histidines and lysines of both HKD motifs, the tyrosyl-DNA phosphodiesterase (Tdp1) that has been implicated in known crystal structures reveal that all four residues are clus- the repair of topoisomerase I covalent complexes with DNA con- tered together in the active center of the enzymes (4, 5). tains two unusual HKD signature motifs that place the enzyme in When a type IB topoisomerase cleaves DNA, the enzyme a distinct class within the PLD superfamily. Mutagenesis studies becomes covalently attached to the DNA through a phosphodi- with the human enzyme in which the invariant histidines and ester bond between a tyrosine residue in the enzyme and the 3Ј lysines of the HKD motifs are changed confirm that these highly end of the cleaved strand (11).
    [Show full text]
  • Mechanism of Action of Ribonuclease H Isolated from Avian Myeloblastosis Virus and Escherichia Coli* (RNA-Dependent DNA Polymerase/Processive Exonuclease/E
    Proc. Nat. Acad. Sci. USA Vol. 70, No. 2, pp. 466-470, February 1973 Mechanism of Action of Ribonuclease H Isolated from Avian Myeloblastosis Virus and Escherichia coli* (RNA-dependent DNA polymerase/processive exonuclease/E. coli endonuclease) JONATHAN P. LEIS, IRA BERKOWER, AND JERARD HURWITZ Department of Developmental Biology and Cancer, Albert Einstein College of Medicine, Bronx, New York 10461 Communicated by Leon A. Heppel, November 16, 1972 ABSTRACT Purified preparations of RNA-dependent nucleotide kinase (13) were prepared by Drs. R. Silber and DNA polymerase isolated from avian myeloblastosis virus V. G. Malathi. [,y-32P]ATP was purchased from New En- contain RNase H activity. Labeled ribohomopolymers are degraded in the presence of their complementary deoxyri- gland Nuclear; labeled polynucleotides and other nucleotides bopolymer, except [3HJpoly(U).poly(dA). The degradation were from Schwarz/Mann Research or Miles Laboratories, products formed from [3Hpoly(A) . poly(dT) were identified Inc. N-cyclohexyl-N'-3(4-methylmorpholinium)ethyl carbo- as oligonucleotides containing 3'-hydroxyl and 5'-phos- diimide p-toluene sulfonate was from Aldrich Chemical Co. pbate termini, while AMP was not detected. The nuclease has been characterized as a processive exonuclease that All other reagents were described (14). requires ends of poly(A) chains for activity. Exonucleolytic Assay for RNase H. Reaction mixtures (0.05 ml) containing attack occurs in both 5' to 3' and 3' to 5' directions. RNase H has also been purified from E. coli. This nu- 1 4mol of Tris - HCl (pH 8.0), 0.5 umol of MgC12, 0.3 jumol of clease degrades all homoribopolymers tested in the pres- dithioerythritol, 2 ,ug of albumin, 0.52 nmol of poly(dT), ence of their complementary deoxyribopolymers to yield 0.56 nmol of [3H]poly(A), and enzyme were incubated for 30 oligonucleotides with 5'-phosphate and 3'-hydroxyl ter- min at 380.
    [Show full text]
  • The Role of Phosphatidylinositol-Specific Phospholipase-C in Plant Defense Signaling
    The Role of Phosphatidylinositol-Specific Phospholipase-C in Plant Defense Signaling Ahmed M. Abd-El-Haliem Thesis committee Promotor Prof. Dr P.J.G.M. de Wit Professor of Phytopathology Wageningen University Co-promotor Dr M.H.A.J. Joosten Associate professor, Laboratory of Phytopathology Wageningen University Other members Prof. Dr H.J. Bouwmeester, Wageningen University Prof. Dr M.W. Prins, University of Amsterdam Prof. Dr G.C. Angenent, Wageningen University Dr S.H.E.J. Gabriёls, Monsanto Holland BV, Wageningen This research was conducted under the auspices of the Graduate School of Experimental Plant Sciences. The Role of Phosphatidylinositol-Specific Phospholipase-C in Plant Defense Signaling Ahmed M. Abd-El-Haliem Thesis submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Thursday 23 October 2014 at 11.00 a.m. in the Aula. Ahmed M. Abd-El-Haliem The Role of Phosphatidylinositol-Specific Phospholipase-C in Plant Defense Signaling, 188 pages. PhD thesis, Wageningen University, Wageningen, NL (2014) With references, with summaries in Dutch and English ISBN 978-94-6257-118-1 TABLE OF CONTENTS CHAPTER 1 General Introduction & Thesis Outline 7 CHAPTER 2 Identification of Tomato Phosphatidylinositol-Specific 19 Phospholipase-C (PI-PLC) Family Members and the Role of PLC4 and PLC6 in HR and Disease Resistance CHAPTER 3 Defense Activation
    [Show full text]
  • Site-Directed Mutations in the Tumor-Associated Cytokine, Autotaxin, Eliminate Nucleotide Phosphodiesterase, Lysophospholipase D, and Motogenic Activities
    [CANCER RESEARCH 63, 2042–2045, May 1, 2003] Site-directed Mutations in the Tumor-associated Cytokine, Autotaxin, Eliminate Nucleotide Phosphodiesterase, Lysophospholipase D, and Motogenic Activities Eunjin Koh,1 Timothy Clair, Elisa C. Woodhouse, Elliott Schiffmann, Lance Liotta, and Mary Stracke Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892 ABSTRACT Cell Culture. A2058 (human melanoma) and COS-1 (green monkey kid- ney) cell lines were maintained as described previously (10). The exo-enzyme autotaxin/NPP2 (ATX/NPP2) is a potent stimulator of Construction of ATX/NPP2 Mutants and Preparation of Mutant Pro- cell migration, invasion, metastasis, and angiogenesis. Recently, ATX/ teins. Site-directed point mutations of ATX/NPP2 were made by overlap exten- NPP2 was found to possess lysophospholipase D (lyso-LPD) activity, gen- sion PCR methodology as described previously (11). ATX/NPP2 cDNA, derived erating the bioactive mediator lysophosphatidic acid from precursors. In from MDA 435 cells, was cloned into pcDNA3.1 vector (pcDNA3.atx/npp2) and the present study, we used site-directed mutagenesis to delineate the active used as a template. PCR was performed using the Platinum Pfx DNA polymerase domain of lysophospholipid catalytic activity and to examine potential (Invitrogen Life Technologies, Inc., Carlsbad, CA) and oligonucleotides designed overlap with the nucleotide phosphodiesterase domain. We found four for each mutant (Table 1). Each mutant plasmid was sequenced to confirm the amino acid residues obligatory for the phosphodiesterase, lyso-PLD, and presence of the mutation and the fidelity of the PCR amplification. COS-1 cells migration-stimulating activities of ATX/NPP2, suggesting that 5؅-nucleo- were transiently transfected with pcDNA3.atx/npp2 or with each mutant plasmid tide phosphodiesterase (PDE) and lyso-PLD share a common reaction using LipofectAMINE 2000 reagent (Invitrogen Life Technologies, Inc.) per mechanism and inviting design of enzymatic inhibitors as therapeutic manufacturer’s protocol.
    [Show full text]